Considering thymalfasin therapy
Condition desk
The short answer: ask for results that fit the condition being treated. Findings from hospital patients or older treatment plans have limits.
In its 2024 review, the Food and Drug Administration (FDA), which oversees US drugs, could not tell from the studies whether thymosin alpha-1 helped with any of the health problems reviewed.
Hepatitis B
Hepatitis B is a viral infection of the liver. A US trial published in 1999 included 97 people and did not show a clear benefit from thymosin alpha-1.
In 2024, the FDA could not tell from the studies whether it helped people with hepatitis B. It noted that approved medicines for hepatitis B exist.
Read the hepatitis B trial recordHepatitis C
Hepatitis C is another viral infection of the liver. In a trial published in 2012, giving thymosin alpha-1 along with an older treatment did not improve cure rates for the group as a whole.
Read the hepatitis C trial recordCOVID
A review published in 2023 combined nine studies of adults in hospital with COVID. It did not find a lower death rate with thymosin alpha-1.
One large study linked use to worse recovery, but this did not prove the drug caused that result. People who were sicker may have been more likely to receive it.
Read the COVID reviewCancer
A 2011 research review suggested that fewer people might die with thymosin alpha-1, but the results were too uncertain to show that it helped people live longer. In 2024, the FDA also found that studies could not show whether it helped with the cancers reviewed.
The studies largely added the peptide to older cancer treatments. They do not support recommending it as a cancer treatment.
Read the cancer review